Patients with severe lupus nephritis who have both diffuse proliferative (class IV) and membranous (class V) lesions on biopsy can be refractory to current monotherapy treatments. Bao et al.

ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Results from randomized controlled trials comparing mycophenolate mofetil versus azathioprine for maintenance therapy in proliferative (class III–IV) lupus nephritis. AZA (120 mg/day ...

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...